Philips Secures FDA Approval for AI-Enhanced Spectral Scanner
Royal Philips has announced receiving FDA 510(k) clearance for its Spectral CT Verida system, which incorporates spectral imaging and AI-driven reconstruction. This system enters the American market following development based on the company's spectral technology.
The Verida system incorporates the Spectral Precise Image technology, which combines a third-generation dual-layer Nano-panel Precise detector with intrinsic noise reduction, along with a deep learning reconstruction engine. This design aims to reduce noise and enhance image quality in scanner applications. The system is intended for use in radiology, interventional radiology, cardiology, and oncology, including low-dose lung cancer screening according to established protocols.
Enhanced Speed and Efficiency in Spectral Imaging
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Leveraging the group's detector-based spectral technology, Verida enables continuous spectral imaging without additional examinations or changes to clinical processes. The system reconstructs 145 images per second, making full examinations available in less than 30 seconds, which is twice as fast as previous capabilities. By simultaneously capturing high and low energy data in a single acquisition, clinicians can access both conventional and spectral results at the same time, allowing for improved tissue characterization and material differentiation without the need for pre-selection or repeated scans.
SectorSanté · Technologie · Dispositifs médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
